Caris Life Sciences, Inc.

Caris is a precision medicine and biotechnology enterprise that develops and commercializes artificial intelligence-powered molecular profiling solutions focused primarily on oncology. Its offerings span the cancer care continuum, including early detection, minimal residual disease tracking, therapy selection, and treatment monitoring, as well as drug target discovery. The core product lines include the MI Profile platform for tissue-based whole exome and whole transcriptome sequencing, the Caris Assure platform for blood-based profiling, and the Precision Whole Genome platform. Caris serves clinical, academic, and biopharmaceutical markets, delivering molecular reports to treating oncologists while collaborating with biopharma companies and academic centers on biomarker research and therapeutic pipelines.

The company provides profiling services across major health systems, academic cancer institutions, and community settings, serving more than 6,000 ordering physicians in the United States. Its clinical solutions are available across U.S. states and Puerto Rico, and internationally via distributors and direct hospital contracts. In addition, Caris coordinates research with cancer centers worldwide through the Caris Precision Oncology Alliance. The provided text does not state the company's headquarters location or official website.

Summary of the business section of Caris Life Sciences's latest annual report, written by StockData.